Michael A. Caligiuri - Publications

Affiliations: 
Ohio State University, Columbus, Columbus, OH 
Area:
Immunology, Molecular Biology, Cell Biology
Website:
https://cancer.osu.edu/research-and-education/find-a-researcher/search-researcher-directory/michael-a-caligiuri

180 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Dong W, Wu X, Ma S, Wang Y, Nalin AP, Zhu Z, Zhang J, Benson DM, He K, Caligiuri MA, Yu J. The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discovery. PMID 31340937 DOI: 10.1158/2159-8290.CD-18-1259  0.32
2019 Xu B, Ma R, Russell L, Yoo JY, Han J, Cui H, Yi P, Zhang J, Nakashima H, Dai H, Chiocca EA, Kaur B, Caligiuri MA, Yu J. Amendments: Publisher Correction: An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature Biotechnology. 37: 102. PMID 30605164 DOI: 10.1038/nbt0119-102c  0.32
2019 Wang Y, Zhang Y, Yi P, Dong W, Nalin AP, Zhang J, Zhu Z, Chen L, Benson DM, Mundy-Bosse BL, Freud AG, Caligiuri MA, Yu J. The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells. Nature Immunology. 20: 10-17. PMID 30538328 DOI: 10.1038/s41590-018-0265-1  0.68
2018 Scoville SD, Freud AG, Caligiuri MA. Cellular pathways in the development of human and murine innate lymphoid cells. Current Opinion in Immunology. 56: 100-106. PMID 30579240 DOI: 10.1016/j.coi.2018.11.003  0.68
2018 Xu B, Ma R, Russell L, Yoo JY, Han J, Cui H, Yi P, Zhang J, Nakashima H, Dai H, Chiocca EA, Kaur B, Caligiuri MA, Yu J. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature Biotechnology. PMID 30475349 DOI: 10.1038/nbt.4302  0.32
2018 Chen L, Youssef Y, Robinson C, Ernst GF, Carson MY, Young KA, Scoville SD, Zhang X, Harris R, Sekhri P, Mansour AG, Chan WK, Nalin AP, Mao HC, Hughes T, ... ... Caligiuri MA, et al. CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity. PMID 30193847 DOI: 10.1016/j.immuni.2018.08.010  0.68
2018 Wang Y, Chu J, Yi P, Dong W, Saultz JN, Wang Y, Wang H, Scoville SD, Zhang J, Wu LC, Deng Y, He X, Mundy-Bosse BL, Freud AG, Wang LS, ... Caligiuri MA, et al. SMAD4 promotes TGF-β-independent NK cell homeostasis and maturation and antitumor immunity. The Journal of Clinical Investigation. PMID 30183689 DOI: 10.1172/JCI121227  0.68
2018 Scoville SD, Nalin AP, Chen L, Chen L, Zhang M, McConnell K, Beceiro Casas S, Ernst G, Traboulsi AA, Hashi N, Williams M, Zhang X, Hughes T, Mishra A, Benson DM, ... ... Caligiuri MA, et al. Human AML activates the AHR pathway to impair NK cell development and function. Blood. PMID 30158248 DOI: 10.1182/blood-2018-03-838474  0.68
2018 Yi L, Chen L, Guo X, Lu T, Wang H, Ji X, Zhang J, Ren Y, Pan P, Kinghorn AD, Huang X, Wang LS, Fan Z, Caligiuri MA, Yu J. A Synthetic Disaccharide Derivative of Diphyllin, TAARD, Activates Human Natural Killer Cells to Secrete Interferon-Gamma Toll-Like Receptor-Mediated NF-κB and STAT3 Signaling Pathways. Frontiers in Immunology. 9: 1509. PMID 30072983 DOI: 10.3389/fimmu.2018.01509  0.32
2018 Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, ... Caligiuri MA, et al. Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Advances. 2: 1818-1827. PMID 30054309 DOI: 10.1182/bloodadvances.2018020388  0.68
2018 Li X, Dong W, Nalin AP, Wang Y, Pan P, Xu B, Zhang Y, Tun S, Zhang J, Wang LS, He X, Caligiuri MA, Yu J. The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells. Oncoimmunology. 7: e1431085. PMID 29872557 DOI: 10.1080/2162402X.2018.1431085  0.32
2018 Chan WK, Kang S, Youssef Y, Glankler EN, Barrett ER, Carter AM, Ahmed EH, Prasad A, Chen L, Zhang J, Benson DM, Caligiuri MA, Yu J. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunology Research. PMID 29769244 DOI: 10.1158/2326-6066.CIR-17-0649  0.32
2018 Wang Y, Dong W, Zhang Y, Caligiuri MA, Yu J. Dependence of innate lymphoid cell 1 development on NKp46. Plos Biology. 16: e2004867. PMID 29702643 DOI: 10.1371/journal.pbio.2004867  0.32
2018 Kim Y, Yoo JY, Lee TJ, Liu J, Yu J, Caligiuri MA, Kaur B, Friedman A. Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29686060 DOI: 10.1073/pnas.1715295115  0.32
2018 Wang Y, Zhang Y, Hughes T, Zhang J, Caligiuri MA, Benson DM, Yu J. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29666301 DOI: 10.1158/1078-0432.CCR-17-3117  0.32
2017 Victor AR, Weigel C, Scoville SD, Chan WK, Chatman K, Nemer MM, Mao C, Young KA, Zhang J, Yu J, Freud AG, Oakes CC, Caligiuri MA. Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. Journal of Immunology (Baltimore, Md. : 1950). PMID 29229679 DOI: 10.4049/jimmunol.1701128  0.68
2017 Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity. 47: 820-833. PMID 29166586 DOI: 10.1016/j.immuni.2017.10.008  0.68
2017 Victor AR, Nalin AP, Dong W, McClory S, Wei M, Mao C, Kladney RD, Youssef Y, Chan WK, Briercheck EL, Hughes T, Scoville SD, Pitarresi JR, Chen C, Manz S, ... ... Caligiuri MA, et al. IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB. Journal of Immunology (Baltimore, Md. : 1950). PMID 28842466 DOI: 10.4049/jimmunol.1601554  0.68
2017 Dai HS, Griffin N, Bolyard C, Mao HC, Zhang J, Cripe TP, Suenaga T, Arase H, Nakano I, Chiocca EA, Kaur B, Yu J, Caligiuri MA. The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Immunity. 47: 159-170.e10. PMID 28723548 DOI: 10.1016/j.immuni.2017.06.019  0.32
2017 Scoville SD, Freud AG, Caligiuri MA. Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells. Frontiers in Immunology. 8: 360. PMID 28396671 DOI: 10.3389/fimmu.2017.00360  0.68
2016 Teng KY, Han J, Zhang X, Hsu SH, He S, Wani N, Barajas J, Snyder LA, Frankel WL, Caligiuri MA, Jacob ST, Yu J, Ghoshal K. Blocking the Ccl2-Ccr2 axis using Ccl2 neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model. Molecular Cancer Therapeutics. PMID 27980102 DOI: 10.1158/1535-7163.MCT-16-0124  0.32
2016 Mace EM, Bigley V, Gunesch JT, Chinn IK, Angelo LS, Care MA, Maisuria S, Keller MD, Togi S, Watkin LB, LaRosa DF, Jhangiani SN, Muzny DM, Stray-Pedersen A, Coban Akdemir Z, ... ... Caligiuri MA, et al. Biallelic mutations in IRF8 impair human NK cell maturation and function. The Journal of Clinical Investigation. PMID 27893462 DOI: 10.1172/JCI86276  0.68
2016 Bolyard CM, Meisen WH, Banasavadi-Siddegowda Y, Hardcastle J, Yoo JY, Wohleb ES, Wojton J, Yu JG, Dubin S, Khosla M, Xu B, Smith JG, Alvarez-Breckenridge C, Pow-Anpongkul P, Pichiorri F, ... ... Caligiuri MA, et al. BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection- implications for Oncolytic Viral Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27852701 DOI: 10.1158/1078-0432.CCR-16-1818  0.32
2016 Mundy-Bosse BL, Scoville SD, Chen L, McConnell K, Mao HC, Ahmed EH, Zorko N, Harvey S, Cole J, Zhang X, Costinean S, Croce CM, Larkin K, Byrd JC, Vasu S, ... ... Caligiuri MA, et al. MicroRNA-29b mediates altered innate immune development in acute leukemia. The Journal of Clinical Investigation. PMID 27775550 DOI: 10.1172/JCI85413  0.68
2016 Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 16: S181-S190.e4. PMID 27521316 DOI: 10.1016/j.clml.2016.02.014  0.68
2016 Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz B, Relation T, Yu JG, Lee TJ, Lotze MT, Zhang J, Croce CM, Yu J, Caligiuri MA, et al. Bortezomib treatment sensitizes oncolytic HSV-1 treated tumors to NK cell immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27390350 DOI: 10.1158/1078-0432.CCR-16-1003  0.32
2016 Freud AG, Keller KA, Scoville SD, Mundy-Bosse BL, Cheng S, Youssef Y, Hughes T, Zhang X, Mo X, Porcu P, Baiocchi RA, Yu J, Carson WE, Caligiuri MA. NKp80 Defines a Critical Step during Human Natural Killer Cell Development. Cell Reports. PMID 27373165 DOI: 10.1016/j.celrep.2016.05.095  0.68
2016 Scoville SD, Mundy-Bosse BL, Zhang MH, Chen L, Zhang X, Keller KA, Hughes T, Chen L, Cheng S, Bergin SM, Mao HC, McClory S, Yu J, Carson WE, Caligiuri MA, et al. A Progenitor Cell Expressing Transcription Factor RORγt Generates All Human Innate Lymphoid Cell Subsets. Immunity. PMID 27178467 DOI: 10.1016/j.immuni.2016.04.007  0.96
2016 Xiao R, Bergin SM, Huang W, Slater AM, Liu X, Judd RT, Lin ED, Widstrom KJ, Scoville SD, Yu J, Caligiuri M, Cao L. Environmental and genetic activation of hypothalamic BDNF modulates T-cell immunity to exert an anticancer phenotype. Cancer Immunology Research. PMID 27045020 DOI: 10.1158/2326-6066.CIR-15-0297  0.96
2016 Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X, Groh V, Whitman SP, Konopitzky R, Kössl C, Bucci D, Lucas DM, Yu J, Caligiuri MA, et al. Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts. Blood. PMID 27013443 DOI: 10.1182/blood-2015-11-680546  0.32
2015 Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, Chiocca EA, Kaur B, Caligiuri MA, Yu J. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Research. PMID 26631269 DOI: 10.1158/0008-5472.CAN-15-0894  0.96
2015 Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, ... ... Caligiuri MA, et al. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. Journal of Immunology (Baltimore, Md. : 1950). 195: 1995-2005. PMID 26238487 DOI: 10.4049/jimmunol.1400084  0.96
2015 Scoville SD, Keller KA, Cheng S, Zhang M, Zhang X, Caligiuri MA, Freud AG. Rapid Column-Free Enrichment of Mononuclear Cells from Solid Tissues. Scientific Reports. 5: 12490. PMID 26223896 DOI: 10.1038/srep12490  0.96
2015 Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso Iii JC, ... ... Caligiuri MA, et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Scientific Reports. 5: 11483. PMID 26155832 DOI: 10.1038/srep11483  0.96
2015 Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, ... ... Caligiuri MA, et al. Targeting leukemia stem cells in vivo with ANTAGOMIR-126 nanoparticles in acute myeloid leukemia. Leukemia. PMID 26055302 DOI: 10.1038/leu.2015.139  0.96
2015 Benson DM, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25999435 DOI: 10.1158/1078-0432.CCR-15-0304  0.96
2015 Deng Y, Kerdiles Y, Chu J, Yuan S, Wang Y, Chen X, Mao H, Zhang L, Zhang J, Hughes T, Deng Y, Zhang Q, Wang F, Zou X, Liu CG, ... ... Caligiuri MA, et al. Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. Immunity. 42: 457-70. PMID 25769609 DOI: 10.1016/j.immuni.2015.02.006  0.96
2015 Kühn MW, Hadler MJ, Daigle SR, Koche RP, Krivtsov AV, Olhava EJ, Caligiuri MA, Huang G, Bradner JE, Pollock RM, Armstrong SA. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 100: e190-3. PMID 25596271 DOI: 10.3324/haematol.2014.115337  0.96
2015 Briercheck EL, Trotta R, Chen L, Hartlage AS, Cole JP, Cole TD, Mao C, Banerjee PP, Hsu HT, Mace EM, Ciarlariello D, Mundy-Bosse BL, Garcia-Cao I, Scoville SD, Yu L, ... ... Caligiuri MA, et al. PTEN is a negative regulator of NK cell cytolytic function. Journal of Immunology (Baltimore, Md. : 1950). 194: 1832-40. PMID 25595786 DOI: 10.4049/jimmunol.1401224  0.96
2014 Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, ... ... Caligiuri MA, et al. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 111: 18679-84. PMID 25512507 DOI: 10.1073/pnas.1422050112  0.96
2014 Deng Y, Chu J, Ren Y, Fan Z, Ji X, Mundy-Bosse B, Yuan S, Hughes T, Zhang J, Cheema B, Camardo AT, Xia Y, Wu LC, Wang LS, He X, ... ... Caligiuri MA, et al. The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling. Journal of Immunology (Baltimore, Md. : 1950). 193: 2994-3002. PMID 25122922 DOI: 10.4049/jimmunol.1302600  0.96
2014 Hughes T, Briercheck EL, Freud AG, Trotta R, McClory S, Scoville SD, Keller K, Deng Y, Cole J, Harrison N, Mao C, Zhang J, Benson DM, Yu J, Caligiuri MA. The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells. Cell Reports. 8: 150-62. PMID 24953655 DOI: 10.1016/j.celrep.2014.05.042  0.96
2014 Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1678-87. PMID 24895995 DOI: 10.1038/mt.2014.101  0.96
2014 Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, et al. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3787-98. PMID 24815720 DOI: 10.1158/1078-0432.CCR-14-0553  0.32
2014 Freud AG, Yu J, Caligiuri MA. Human natural killer cell development in secondary lymphoid tissues. Seminars in Immunology. 26: 132-7. PMID 24661538 DOI: 10.1016/j.smim.2014.02.008  0.96
2014 Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, ... ... Caligiuri MA, et al. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia. 28: 1754-8. PMID 24651097 DOI: 10.1038/leu.2014.114  0.96
2014 Benson DM, Caligiuri MA. Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunology Research. 2: 99-104. PMID 24592397 DOI: 10.1158/2326-6066.CIR-13-0219  0.32
2014 Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, ... ... Caligiuri MA, et al. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. The Journal of Clinical Investigation. 124: 1512-24. PMID 24590286 DOI: 10.1172/JCI70921  0.96
2014 Kolitz JE, George SL, Benson DM, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, ... Caligiuri MA, et al. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 120: 1010-7. PMID 24382782 DOI: 10.1002/cncr.28516  0.96
2014 Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, ... ... Caligiuri MA, et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 548-56. PMID 24378410 DOI: 10.1200/JCO.2013.50.6337  0.96
2014 Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, ... ... Caligiuri MA, et al. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 28: 1252-8. PMID 24326683 DOI: 10.1038/leu.2013.371  0.96
2013 Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends in Immunology. 34: 573-82. PMID 24055329 DOI: 10.1016/j.it.2013.07.005  0.96
2013 Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, ... ... Caligiuri MA, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/JCI68951  0.96
2013 Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 122: 3034-44. PMID 23970380 DOI: 10.1182/blood-2013-04-495374  0.96
2013 Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122: 1923-34. PMID 23926298 DOI: 10.1182/blood-2013-03-492181  0.96
2013 Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, ... ... Caligiuri MA, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 122: 2539-49. PMID 23886836 DOI: 10.1182/blood-2013-06-507947  0.96
2013 Mendler JH, Maharry K, Becker H, Eisfeld AK, Senter L, Mrózek K, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Khalife J, Caligiuri MA, Klisovic RB, Moore JO, Carter TH, et al. In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline. Haematologica. 98: e92-4. PMID 23753029 DOI: 10.3324/haematol.2013.089904  0.96
2013 Alvarez-Breckenridge CA, Yu J, Caligiuri MA, Chiocca EA. Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology. 2: e23658. PMID 23734319 DOI: 10.4161/onci.23658  0.96
2013 Park IK, Trotta R, Yu J, Caligiuri MA. Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development. European Journal of Immunology. 43: 2750-5. PMID 23722894 DOI: 10.1002/eji.201243116  0.32
2013 Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, ... ... Caligiuri MA, et al. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. Leukemia. 27: 2379-82. PMID 23660685 DOI: 10.1038/leu.2013.147  0.96
2013 Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, ... ... Caligiuri MA, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2086-93. PMID 23650424 DOI: 10.1200/JCO.2012.45.6228  0.96
2013 He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM, Hofmeister CC, He X, ... ... Caligiuri MA, et al. MicroRNAs activate natural killer cells through Toll-like receptor signaling. Blood. 121: 4663-71. PMID 23580661 DOI: 10.1182/blood-2012-07-441360  0.96
2013 Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. Journal of Hematology & Oncology. 6: 21. PMID 23497456 DOI: 10.1186/1756-8722-6-21  0.96
2013 Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2355-67. PMID 23493348 DOI: 10.1158/1078-0432.CCR-12-3191  0.96
2013 Trotta R, Chen L, Costinean S, Josyula S, Mundy-Bosse BL, Ciarlariello D, Mao C, Briercheck EL, McConnell KK, Mishra A, Yu L, Croce CM, Caligiuri MA. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood. 121: 3126-34. PMID 23422749 DOI: 10.1182/blood-2012-12-467597  0.68
2013 Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Büchner T, ... ... Caligiuri MA, et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1172-81. PMID 23382473 DOI: 10.1200/JCO.2012.44.3184  0.96
2013 Li Y, Gao L, Luo X, Wang L, Gao X, Wang W, Sun J, Dou L, Li J, Xu C, Wang L, Zhou M, Jiang M, Zhou J, Caligiuri MA, et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood. 121: 499-509. PMID 23223432 DOI: 10.1182/blood-2012-07-444729  0.96
2013 Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 27: 871-8. PMID 23178755 DOI: 10.1038/leu.2012.342  0.96
2013 Schwind S, Edwards CG, Nicolet D, Mrózek K, Maharry K, Wu YZ, Paschka P, Eisfeld AK, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, ... ... Caligiuri MA, et al. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood. 121: 385-91. PMID 23160462 DOI: 10.1182/blood-2012-07-442772  0.96
2013 Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, ... ... Caligiuri MA, et al. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood. 121: 159-69. PMID 23100311 DOI: 10.1182/blood-2012-05-428573  0.96
2012 Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, ... ... Caligiuri MA, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine. 18: 1827-34. PMID 23178246 DOI: 10.1038/nm.3013  0.96
2012 Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X, Fisk H, Wu LC, Hickey C, Chandler JC, ... ... Caligiuri MA, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 22: 645-55. PMID 23153537 DOI: 10.1016/j.ccr.2012.09.009  0.96
2012 Benson DM, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 120: 4324-33. PMID 23033266 DOI: 10.1182/blood-2012-06-438028  0.96
2012 Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. The Journal of Clinical Investigation. 122: 2871-83. PMID 22820288 DOI: 10.1172/JCI63539  0.96
2012 Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu YZ, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, ... ... Caligiuri MA, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 120: 2466-74. PMID 22786882 DOI: 10.1182/blood-2012-05-429175  0.96
2012 Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, ... ... Caligiuri MA, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3109-18. PMID 22753902 DOI: 10.1200/JCO.2011.40.6652  0.96
2012 Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H, ... Caligiuri MA, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proceedings of the National Academy of Sciences of the United States of America. 109: E2110-6. PMID 22753494 DOI: 10.1073/pnas.1209414109  0.96
2012 Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, ... ... Caligiuri MA, et al. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood. 120: 1118-29. PMID 22740449 DOI: 10.1182/blood-2012-02-412379  0.96
2012 Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, ... ... Caligiuri MA, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 119: 6025-31. PMID 22566605 DOI: 10.1182/blood-2012-03-413898  0.96
2012 Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, ... ... Caligiuri MA, et al. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood. 120: 249-58. PMID 22529287 DOI: 10.1182/blood-2012-02-408492  0.96
2012 McClory S, Hughes T, Freud AG, Briercheck EL, Martin C, Trimboli AJ, Yu J, Zhang X, Leone G, Nuovo G, Caligiuri MA. Evidence for a stepwise program of extrathymic T cell development within the human tonsil. The Journal of Clinical Investigation. 122: 1403-15. PMID 22378041 DOI: 10.1172/JCI46125  0.96
2012 Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, Ha YP, Bergin S, Hwang C, Fernandez SA, Kaur B, Caligiuri MA, Chiocca EA. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. Journal of Virology. 86: 4566-77. PMID 22318143 DOI: 10.1128/JVI.05545-11  0.96
2012 Alvarez-Breckenridge CA, Yu J, Kaur B, Caligiuri MA, Chiocca EA. Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Advances in Virology. 2012: 702839. PMID 22312364 DOI: 10.1155/2012/702839  0.96
2012 Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, ... ... Caligiuri MA, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 742-50. PMID 22291079 DOI: 10.1200/JCO.2011.39.2092  0.96
2012 Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, Kurozumi K, Glorioso JC, Caligiuri MA, Kaur B. Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Research. 72: 1353-62. PMID 22282654 DOI: 10.1158/0008-5472.CAN-11-2526  0.96
2012 Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, ... ... Caligiuri MA, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 119: 2314-24. PMID 22251480 DOI: 10.1182/blood-2011-10-386235  0.96
2011 Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, ... ... Caligiuri MA, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 118: 6920-9. PMID 22031865 DOI: 10.1182/blood-2011-08-368225  0.96
2011 Benson DM, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 118: 6387-91. PMID 22031859 DOI: 10.1182/blood-2011-06-360255  0.96
2011 Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrózek K, Maharry K, Becker H, Metzeler KH, Whitman SP, Wu YZ, Powell BL, Baer MR, Kolitz JE, Carroll AJ, Larson RA, ... Caligiuri MA, et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood. 118: 4188-98. PMID 21828125 DOI: 10.1182/blood-2011-06-357764  0.96
2011 Mehta P, Wavreille AS, Justiniano SE, Marsh RL, Yu J, Burry RW, Jarjoura D, Eubank T, Caligiuri MA, Butchar JP, Tridandapani S. LyGDI, a novel SHIP-interacting protein, is a negative regulator of FcγR-mediated phagocytosis. Plos One. 6: e21175. PMID 21695085 DOI: 10.1371/journal.pone.0021175  0.96
2011 Becker H, Maharry K, Radmacher MD, Mrózek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, ... ... Caligiuri MA, et al. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica. 96: 1488-95. PMID 21659357 DOI: 10.3324/haematol.2011.041905  0.96
2011 Liu S, Madiai F, Hackshaw KV, Allen CE, Carl J, Huschart E, Karanfilov C, Litsky A, Hickey CJ, Marcucci G, Huja S, Agarwal S, Yu J, Caligiuri MA, Wu LC. The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis. Plos One. 6: e17161. PMID 21390242 DOI: 10.1371/journal.pone.0017161  0.96
2011 Yu J, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu S, Yokohama A, Trotta R, Marcucci G, Benson DM, ... ... Caligiuri MA, et al. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. The Journal of Clinical Investigation. 121: 1456-70. PMID 21364281 DOI: 10.1172/JCI43242  0.96
2011 Kannan Y, Yu J, Raices RM, Seshadri S, Wei M, Caligiuri MA, Wewers MD. IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells. Blood. 117: 2855-63. PMID 21224476 DOI: 10.1182/blood-2010-07-294702  0.4
2011 Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science (New York, N.Y.). 331: 44-9. PMID 21212348 DOI: 10.1126/science.1198687  0.96
2011 Trotta R, Ciarlariello D, Dal Col J, Mao H, Chen L, Briercheck E, Yu J, Zhang J, Perrotti D, Caligiuri MA. The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. Blood. 117: 2378-84. PMID 21156847 DOI: 10.1182/blood-2010-05-285130  0.32
2010 Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, ... ... Caligiuri MA, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 5257-64. PMID 21079133 DOI: 10.1200/JCO.2010.29.2953  0.96
2010 Smith MA, Maurin M, Cho HI, Becknell B, Freud AG, Yu J, Wei S, Djeu J, Celis E, Caligiuri MA, Wright KL. PRDM1/Blimp-1 controls effector cytokine production in human NK cells. Journal of Immunology (Baltimore, Md. : 1950). 185: 6058-67. PMID 20944005 DOI: 10.4049/jimmunol.1001682  0.96
2010 Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, ... ... Caligiuri MA, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116: 5660-9. PMID 20841507 DOI: 10.1182/blood-2010-06-290536  0.96
2010 Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, ... ... Caligiuri MA, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116: 3622-6. PMID 20656931 DOI: 10.1182/blood-2010-05-283648  0.96
2010 Hughes T, Becknell B, Freud AG, McClory S, Briercheck E, Yu J, Mao C, Giovenzana C, Nuovo G, Wei L, Zhang X, Gavrilin MA, Wewers MD, Caligiuri MA. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity. 32: 803-14. PMID 20620944 DOI: 10.1016/j.immuni.2010.06.007  0.96
2010 Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, ... ... Caligiuri MA, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 116: 2286-94. PMID 20460501 DOI: 10.1182/blood-2010-02-271874  0.96
2010 Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, ... ... Caligiuri MA, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116: 788-92. PMID 20442368 DOI: 10.1182/blood-2010-01-262543  0.96
2010 Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, ... ... Caligiuri MA, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 17: 333-47. PMID 20385359 DOI: 10.1016/j.ccr.2010.03.008  0.96
2010 Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, ... ... Caligiuri MA, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2348-55. PMID 20368543 DOI: 10.1200/JCO.2009.27.3730  0.96
2010 Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, ... ... Caligiuri MA, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 140: 652-65. PMID 20211135 DOI: 10.1016/j.cell.2010.01.007  0.96
2010 Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, Caligiuri MA. In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. Journal of Immunology (Baltimore, Md. : 1950). 184: 2769-75. PMID 20142363 DOI: 10.4049/jimmunol.0900685  0.96
2010 Freud AG, Caligiuri MA. Purification of human NK cell developmental intermediates from lymph nodes and tonsils. Methods in Molecular Biology (Clifton, N.J.). 612: 1-14. PMID 20033630 DOI: 10.1007/978-1-60761-362-6_1  0.96
2010 Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, ... ... Caligiuri MA, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 596-604. PMID 20026798 DOI: 10.1200/JCO.2009.25.1496  0.96
2010 Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, ... Caligiuri MA, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 115: 1204-13. PMID 19965644 DOI: 10.1182/blood-2009-06-229039  0.96
2010 Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood. 115: 274-81. PMID 19897577 DOI: 10.1182/blood-2009-04-215491  0.32
2010 Yokohama A, Mishra A, Mitsui T, Becknell B, Johns J, Curphey D, Blaser BW, Vandeusen JB, Mao H, Yu J, Caligiuri MA. A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. Leukemia Research. 34: 203-9. PMID 19660811 DOI: 10.1016/j.leukres.2009.06.031  0.96
2009 Yu J, Wei M, Mao H, Zhang J, Hughes T, Mitsui T, Park IK, Hwang C, Liu S, Marcucci G, Trotta R, Benson DM, Caligiuri MA. CD94 defines phenotypically and functionally distinct mouse NK cell subsets. Journal of Immunology (Baltimore, Md. : 1950). 183: 4968-74. PMID 19801519 DOI: 10.4049/jimmunol.0900907  0.96
2009 Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 114: 2667-77. PMID 19553639 DOI: 10.1182/blood-2009-02-206532  0.96
2009 Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3198-204. PMID 19451432 DOI: 10.1200/JCO.2008.20.6110  0.96
2009 Yu J, Ershler M, Yu L, Wei M, Hackanson B, Yokohama A, Mitsui T, Liu C, Mao H, Liu S, Liu Z, Trotta R, Liu CG, Liu X, Huang K, ... ... Caligiuri MA, et al. TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia. Blood. 113: 5558-67. PMID 19329776 DOI: 10.1182/blood-2009-02-205732  0.96
2009 Hughes T, Becknell B, McClory S, Briercheck E, Freud AG, Zhang X, Mao H, Nuovo G, Yu J, Caligiuri MA. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood. 113: 4008-10. PMID 19244159 DOI: 10.1182/blood-2008-12-192443  0.96
2009 Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. British Journal of Haematology. 144: 848-55. PMID 19183192 DOI: 10.1111/j.1365-2141.2008.07548.x  0.96
2009 Benson DM, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 113: 2706-14. PMID 19060242 DOI: 10.1182/blood-2008-05-159285  0.96
2009 Park IK, Giovenzana C, Hughes TL, Yu J, Trotta R, Caligiuri MA. The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. Blood. 113: 2470-7. PMID 18840707 DOI: 10.1182/blood-2008-05-157073  0.96
2008 Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5078-87. PMID 18809607 DOI: 10.1200/JCO.2008.17.5554  0.96
2008 Richards J, McNally B, Fang X, Caligiuri MA, Zheng P, Liu Y. Tumor growth decreases NK and B cells as well as common lymphoid progenitor. Plos One. 3: e3180. PMID 18784839 DOI: 10.1371/journal.pone.0003180  0.96
2008 Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. Journal of Immunology (Baltimore, Md. : 1950). 181: 3784-92. PMID 18768831  0.32
2008 Dorrance AM, Liu S, Chong A, Pulley B, Nemer D, Guimond M, Yuan W, Chang D, Whitman SP, Marcucci G, Caligiuri MA. The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. Blood. 112: 2508-11. PMID 18617636 DOI: 10.1182/blood-2008-01-134338  0.44
2008 Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4934-9. PMID 18591543 DOI: 10.1200/JCO.2008.17.0472  0.96
2008 Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, ... Caligiuri MA, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 112: 2013-6. PMID 18566324 DOI: 10.1182/blood-2008-01-128595  0.96
2008 Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4595-602. PMID 18559874 DOI: 10.1200/JCO.2007.15.2058  0.96
2008 Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, ... ... Caligiuri MA, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. The New England Journal of Medicine. 358: 1919-28. PMID 18450603 DOI: 10.1056/NEJMoa074256  0.96
2008 Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, et al. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 569-78. PMID 18223233 DOI: 10.1158/1078-0432.CCR-07-1006  0.96
2008 Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 111: 4723-30. PMID 18182577 DOI: 10.1182/blood-2007-07-099531  0.96
2008 Kondadasula SV, Roda JM, Parihar R, Yu J, Lehman A, Caligiuri MA, Tridandapani S, Burry RW, Carson WE. Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. Blood. 111: 4173-83. PMID 18174382 DOI: 10.1182/blood-2007-01-068908  0.32
2008 Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, ... ... Caligiuri MA, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 111: 2364-73. PMID 18083845 DOI: 10.1182/blood-2007-08-110171  0.96
2008 Swanson KD, Winter JM, Reis M, Bentires-Alj M, Greulich H, Grewal R, Hruban RH, Yeo CJ, Yassin Y, Iartchouk O, Montgomery K, Whitman SP, Caligiuri MA, Loh ML, Gilliland DG, et al. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes, Chromosomes & Cancer. 47: 253-9. PMID 18064648 DOI: 10.1002/gcc.20527  0.96
2008 Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 111: 1552-9. PMID 17940205 DOI: 10.1182/blood-2007-08-107946  0.96
2008 Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood. 111: 816-28. PMID 17925491 DOI: 10.1182/blood-2007-05-090472  0.96
2007 Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, Leone G. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 104: 15400-5. PMID 17881568 DOI: 10.1073/pnas.0706307104  0.96
2007 Trotta R, Ciarlariello D, Dal Col J, Allard J, Neviani P, Santhanam R, Mao H, Becknell B, Yu J, Ferketich AK, Thomas B, Modi A, Blaser BW, Perrotti D, Caligiuri MA. The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. The Journal of Experimental Medicine. 204: 2397-405. PMID 17875674 DOI: 10.1084/jem.20070419  0.96
2007 Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, ... ... Caligiuri MA, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/JCI31095  0.96
2007 Becknell B, Hughes TL, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesús ML, Alghothani M, Benson DM, Lehman A, Jarjoura D, Perrotti D, Bates MD, Caligiuri MA. Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells. Blood. 109: 2481-7. PMID 17110450 DOI: 10.1182/blood-2006-10-050096  0.96
2006 Freud AG, Caligiuri MA. Human natural killer cell development. Immunological Reviews. 214: 56-72. PMID 17100876 DOI: 10.1111/j.1600-065X.2006.00451.x  0.96
2006 Dorrance AM, Liu S, Yuan W, Becknell B, Arnoczky KJ, Guimond M, Strout MP, Feng L, Nakamura T, Yu L, Rush LJ, Weinstein M, Leone G, Wu L, Ferketich A, ... ... Caligiuri MA, et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. The Journal of Clinical Investigation. 116: 2707-16. PMID 16981007 DOI: 10.1172/JCI25546  0.44
2006 Shah MH, Freud AG, Benson DM, Ferkitich AK, Dezube BJ, Bernstein ZP, Caligiuri MA. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3993-6. PMID 16818697 DOI: 10.1158/1078-0432.CCR-06-0268  0.96
2006 Blaser BW, Schwind NR, Karol S, Chang D, Shin S, Roychowdhury S, Becknell B, Ferketich AK, Kusewitt DF, Blazar BR, Caligiuri MA. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood. 108: 2463-9. PMID 16757683 DOI: 10.1182/blood-2006-04-019059  0.96
2006 Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA. Evidence for discrete stages of human natural killer cell differentiation in vivo. The Journal of Experimental Medicine. 203: 1033-43. PMID 16606675 DOI: 10.1084/jem.20052507  0.96
2006 VanDeusen JB, Shah MH, Becknell B, Blaser BW, Ferketich AK, Nuovo GJ, Ahmer BM, Durbin J, Caligiuri MA. STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo. European Journal of Immunology. 36: 623-30. PMID 16482512 DOI: 10.1002/eji.200535241  0.96
2005 Roychowdhury S, Caligiuri MA. Cytokine therapy for cancer: antigen presentation. Cancer Treatment and Research. 123: 249-66. PMID 16211874  0.96
2005 Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, Caligiuri MA. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood. 106: 2433-5. PMID 15976176 DOI: 10.1182/blood-2005-04-1597  0.96
2005 Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity. 22: 295-304. PMID 15780987 DOI: 10.1016/j.immuni.2005.01.013  0.96
2005 Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, Klisovic MI, Maharry K, Guimond M, Strout MP, Becknell B, Dorrance A, Klisovic RB, Plass C, Bloomfield CD, ... ... Caligiuri MA, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood. 106: 345-52. PMID 15774615 DOI: 10.1182/blood-2005-01-0204  0.96
2005 Dierksheide JE, Baiocchi RA, Ferketich AK, Roychowdhury S, Pelletier RP, Eisenbeis CF, Caligiuri MA, VanBuskirk AM. IFN-γ gene polymorphisms associate with development of EBV + lymphoproliferative disease in hu PBL-SCID mice Blood. 105: 1558-1565. PMID 15498860 DOI: 10.1182/blood-2003-07-2476  0.96
2005 May KF, Roychowdhury S, Bhatt D, Kocak E, Bai XF, Liu JQ, Ferketich AK, Martin EW, Caligiuri MA, Zheng P, Liu Y. Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. Blood. 105: 1114-20. PMID 15486062 DOI: 10.1182/blood-2004-07-2561  0.96
2005 Blaser BW, Roychowdhury S, Kim DJ, Schwind NR, Bhatt D, Yuan W, Kusewitt DF, Ferketich AK, Caligiuri MA, Guimond M. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood. 105: 894-901. PMID 15374888 DOI: 10.1182/blood-2004-05-1687  0.96
2004 Cooper MA, Caligiuri MA. Isolation and characterization of human natural killer cell subsets Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. PMID 18432933  0.96
2004 Roychowdhury S, May KF, Tzou KS, Lin T, Bhatt D, Freud AG, Guimond M, Ferketich AK, Liu Y, Caligiuri MA. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Research. 64: 8062-7. PMID 15520217 DOI: 10.1158/0008-5472.CAN-04-1860  0.96
2004 Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, ... Caligiuri MA, et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. Journal of the National Cancer Institute. 96: 1447-57. PMID 15467034 DOI: 10.1093/jnci/djh271  0.96
2004 Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6101-10. PMID 15447996 DOI: 10.1158/1078-0432.CCR-04-0525  0.96
2004 Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends in Immunology. 25: 47-52. PMID 14698284  0.92
2003 Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF, ... Caligiuri MA, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Research. 63: 965-71. PMID 12615710  0.96
2003 VanDeusen JB, Caligiuri MA. New developments in anti-tumor efficacy and malignant transformation of human natural killer cells. Current Opinion in Hematology. 10: 55-9. PMID 12483112  0.76
2003 Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 101: 3052-7. PMID 12480696 DOI: 10.1182/blood-2002-09-2876  0.92
2002 Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 100: 3633-8. PMID 12393617 DOI: 10.1182/blood-2001-12-0293  0.96
2002 Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, Caligiuri MA. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood. 100: 2341-8. PMID 12239141 DOI: 10.1182/blood-2002-01-0210  0.96
2002 Cooper MA, Caligiuri MA. Immunologic manipulation in AML: From bench to bedside Leukemia. 16: 736-737. PMID 11960357 DOI: 10.1038/sj/leu/2402411  0.96
2002 Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine & Growth Factor Reviews. 13: 169-83. PMID 11900992  0.92
2002 Rush LJ, Heinonen K, Mrózek K, Wolf BJ, Abdel-Rahman M, Szymanska J, Peltomäki P, Kapadia F, Bloomfield CD, Caligiuri MA, Plass C. Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line. Blood. 99: 1874-6. PMID 11871388 DOI: 10.1182/blood.V99.5.1874  0.96
2001 Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, Caligiuri MA, Chalmers JJ. Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system. Cytometry. 45: 285-93. PMID 11746098 DOI: 10.1002/1097-0320(20011201)45:4<285::AID-CYTO10018>3.0.CO;2-W  0.96
2001 Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K, Mrózek K, Sill H, Knuutila S, Kolitz JE, Archer KJ, Caligiuri MA, Bloomfield CD, de La Chapelle A. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proceedings of the National Academy of Sciences of the United States of America. 98: 13901-6. PMID 11707601 DOI: 10.1073/pnas.241525498  0.96
2001 Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends in Immunology. 22: 633-40. PMID 11698225  0.92
2001 Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, Vourganti S, Sekula T, O'Brien M, Moeschberger M, Caligiuri MA. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. The Journal of Clinical Investigation. 108: 887-94. PMID 11560958 DOI: 10.1172/JCI12932  0.96
2001 Smiraglia DJ, Rush LJ, Frühwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, Caligiuri MA, Plass C. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies Human Molecular Genetics. 10: 1413-1419. PMID 11440994  0.96
2001 Fehniger TA, Suzuki K, VanDeusen JB, Cooper MA, Freud AG, Caligiuri MA. Fatal leukemia in interleukin-15 transgenic mice. Blood Cells, Molecules & Diseases. 27: 223-30. PMID 11358383 DOI: 10.1006/bcmd.2001.0379  0.96
2001 Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 97: 3146-51. PMID 11342442 DOI: 10.1182/blood.V97.10.3146  0.96
2001 Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. European Journal of Immunology. 31: 792-801. PMID 11241284 DOI: 10.1002/1521-4141(200103)31:3<792::AID-IMMU792>3.0.CO;2-U  0.92
2001 Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. The Journal of Experimental Medicine. 193: 219-31. PMID 11208862 DOI: 10.1084/jem.193.2.219  0.96
2001 Whitman SP, Strout MP, Marcucci G, Freud AG, Culley LL, Zeleznik-Le NJ, Mrózek K, Theil KS, Kees UR, Bloomfield CD, Caligiuri MA. The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia. Cancer Research. 61: 59-63. PMID 11196198  0.96
2000 Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G, Yu H, Baumann H, Shah MH, Cooper MA, Durbin J, Caligiuri MA. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood. 96: 1465-73. PMID 10942393  0.92
2000 Fehniger TA, Bluman EM, Porter MM, Mrózek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. The Journal of Clinical Investigation. 106: 117-24. PMID 10880055 DOI: 10.1172/JCI6218  0.92
2000 Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. Journal of Immunology (Baltimore, Md. : 1950). 164: 1643-7. PMID 10657604  0.92
2000 Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics. 24: 132-8. PMID 10655057 DOI: 10.1038/72785  0.96
1999 Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. Journal of Immunology (Baltimore, Md. : 1950). 162: 4511-20. PMID 10201989  0.92
Show low-probability matches.